Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Omecamtiv Mecarbil · CK-1827452, AMG-423

Small molecule · developed by Cytokinetics

Phase 3 Most advanced trial

CYTK Developer

5 Registered trials

What is Omecamtiv Mecarbil?

Omecamtiv Mecarbil is an investigational small-molecule drug studied in Heart Failure, Myocardial Ischemia, Angina Pectoris.

At a glance

Also known as: CK-1827452, AMG-423
Drug type: Small molecule
Therapy area: Cardiovascular
Developer: Cytokinetics (CYTK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 2M19539ERK

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06736574	Phase 3	Heart Failure	Recruiting	CYTK
NCT03759392	Phase 3	Heart Failure With Reduced Ejection Fraction	Completed	CYTK
NCT01786512	Phase 2	Modified Release Oral Formulation	Completed	CYTK
NCT00682565	Phase 2	Heart Failure	Completed	CYTK
NCT00624442	Phase 2	Heart Failure	Completed	CYTK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Angina PectorisChronic Heart FailureEchocardiogramHeart FailureHeart Failure With Reduced Ejection FractionHistory of Chronic Heart FailureLeft Ventricular Ejection FractionLeft Ventricular Systolic DysfunctionModified Release Oral FormulationMyocardial IschemiaPharmacokinetics

More from Cytokinetics

Aficamten FDA approved AMG 423 Phase 1 CK-3828136 Phase 1 Reldesemtiv Phase 3 SB-743921 Phase 1/2 Tirasemtiv Phase 3 Ulacamten Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CYTK page.

Follow CYTK, the company behind Omecamtiv Mecarbil

See CYTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CYTK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z